Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria :
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Ascendant Resources Announces Results of Annual General Meeting of Shareholders

Ascendant Resources Announces Results of Annual General Meeting of Shareholders

Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario

A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Romios Begins Field Work to Follow-Up New Satellite Image Study by Photosat Outlining Significant Alteration Zones at the Kinkaid Copper-Gold-Silver Property, Nevada, USA

Romios Begins Field Work to Follow-Up New Satellite Image Study by Photosat Outlining Significant Alteration Zones at the Kinkaid Copper-Gold-Silver Property, Nevada, USA

Romios Gold Resources Inc. (TSXV: RG) (OTCQB: RMIOF) (FSE: D4R) ("Romios Gold" or the "Company") is pleased to report that Photosat has recently completed an in-depth, advanced re-interpretation of the previously reported Short Wave Infrared (SWIR) satellite image study that outlined the specific alteration minerals associated with mineralization on Romios' Kinkaid property in Mineral County, Nevada.

This new work used proprietary Deep Learning Technology to differentiate the types of sericite associated with the known mineralized structures and then outlined the same signature on several major, previously unrecognized, linear alteration zones potentially associated with additional mineralized vein systems.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
StrategX Elements Corp. Announces $4.5M Charity Flow-Through Private Placement

StrategX Elements Corp. Announces $4.5M Charity Flow-Through Private Placement

StrategX Elements Corp. (CSE: STGX) ("StrategX" or the "Company"), announces that it proposes to undertake an up to $4,500,000 non-brokered private placement of flow-through shares (the "Charity FT Shares") to be sold to charitable purchasers at a price of $0.30 per Charity FT Share. The gross proceeds received from the sale of the Charity FT Shares will be used for work programs on the Company's exploration properties. All securities issued and sold under this financing will be subject to a four-month-and-one-day hold period under securities laws in Canada. The Company expects to complete this Charity FT Share financing on or before June 24, 2024.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Heritage Mining Announces up to $750,000 Non-Brokered Private Placement with lead orders over C$500,000

Heritage Mining Announces up to $750,000 Non-Brokered Private Placement with lead orders over C$500,000

(TheNewswire)

Heritage Mining Ltd.

NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Noble Acquires Mann Twp Claims and Spruce Ridge Units, and Agrees to Purchase Interest in Carnegie Twp Claims

Noble Acquires Mann Twp Claims and Spruce Ridge Units, and Agrees to Purchase Interest in Carnegie Twp Claims

(TheNewswire)

Noble Mineral Exploration Inc.

Toronto, Ontario TheNewswire - June 11, 2024 Noble Mineral Exploration Inc. ( "Noble" or the "Company" ) (TSX-V:NOB, FRANKFURT: NB7, OTCQB:NLPXF) is pleased to provide the following updates:

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
End of the BAPE Public Information Period 

End of the BAPE Public Information Period 

Falco Resources Ltd. (TSX.V: FPC) (" Falco " or the " Corporation ") would like to thank all those who participated and enriched the discussions during the public information period of the Bureau d'audiences publiques sur l'environnement (BAPE) and reiterates its commitment to working closely with the community, environmental groups, and authorities for the success of Falco's Horne 5 Project (" Falco's Horne 5 Project " or the " Project" ).

This information period, which was held from April 24 to June 10, 2024, allowed citizens, groups, the municipality and organizations to learn about the various environmental, economic and social aspects of the Project. During this period, it was also possible to make requests for public consultation or mediation to the Minister of the Environment, the Fight against Climate Change, Wildlife and Parks.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×